A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Gating or Residual Function Mutation (F/G and F/RF Genotypes)

• Codi protocol: VX18-445-110
• Codi EudraCT: 2019-000833-37
• Grup de recerca: Pneumologia
• Servei: Pneumologia
• Investigador/a principal:  Álvarez Fernandez, Antonio
• Fase: Fase III
• Estat: Reclutant voluntaris